{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:22:28Z","timestamp":1791400948876,"version":"4.3.3"},"reference-count":58,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T00:00:00Z","timestamp":1624665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Type 2 inflammation is common in numerous atopic\/allergic diseases and can be identified by elevated biomarker levels. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin\u20104 and interleukin\u201013, key and central drivers of type 2 inflammation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>Assessment of dupilumab effect on type 2 inflammatory biomarkers in atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic esophagitis (EoE).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were extracted from three randomized placebo\u2010controlled trials of dupilumab in AD (NCT02277743, <jats:italic>N\u00a0=\u00a0671<\/jats:italic>; NCT02277769, <jats:italic>N<\/jats:italic>\u00a0=\u00a0708; NCT02260986, <jats:italic>N<\/jats:italic>\u00a0=\u00a0740); and one each in asthma (NCT02414854, <jats:italic>N<\/jats:italic>\u00a0=\u00a01902); CRSwNP (NCT02898454, <jats:italic>N<\/jats:italic>\u00a0=\u00a0448); and EoE (NCT02379052, <jats:italic>N<\/jats:italic>\u00a0=\u00a047). Biomarkers assessed were serum thymus and activation\u2010regulated chemokine (TARC), plasma eotaxin\u20103, serum total immunoglobulin E (IgE), serum periostin and blood eosinophil count.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Dupilumab versus placebo significantly suppressed most type 2 inflammatory biomarker levels across all studies\/indications where data were assessed. Reductions in serum TARC, plasma eotaxin\u20103 and serum periostin occurred rapidly, whereas reductions in serum total IgE were more gradual. Across diseases, at the end of treatment, median percentage change from baseline in TARC levels ranged from \u221224.8% to \u221288.6% (placebo +2.6% to \u221253.6%); \u221238.2% to \u221251.5% (placebo +8.3% to \u22120.16%) in eotaxin\u20103; \u221224.8% to \u221276.7% (placebo +8.3% to \u22124.4%) in total IgE; and \u221213.6% to \u221241.1% (placebo +10.1% to \u22126.94%) in periostin levels. Blood eosinophil responses to dupilumab varied by disease, with minimal changes in AD in the SOLO studies (median percentage change from baseline to end of treatment: 0% [95% CI: \u221215.8, 0]); transient increases followed by decreases to below\u2010baseline levels in asthma (\u221214.6% [\u221220.0, \u22127.7]) and CRSwNP (\u221229.4% [\u221240.0, \u221216.3]); and significant decreases in EoE (\u221250.0% [\u221250.0, \u221233.3]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion and clinical relevance<\/jats:title><jats:p>Dupilumab reduced levels of type 2 biomarkers across clinical studies in patients with AD, asthma, CRSwNP and EoE.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cea.13954","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T15:32:06Z","timestamp":1622043126000},"page":"915-931","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":180,"title":["Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases"],"prefix":"10.1111","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1236-5245","authenticated-orcid":false,"given":"Jennifer D.","family":"Hamilton","sequence":"first","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivan","family":"Harel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian N.","family":"Swanson","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Brian","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Chen","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan S.","family":"Rice","sequence":"additional","affiliation":[{"name":"Sanofi Cambridge MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Amin","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Ardeleanu","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Radin","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Shumel","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naimish","family":"Patel","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Pirozzi","sequence":"additional","affiliation":[{"name":"Sanofi Bridgewater NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda","family":"Mannent","sequence":"additional","affiliation":[{"name":"Sanofi Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil M. H.","family":"Graham","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals, Inc Tarrytown NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,6,26]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1298443"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-019-08733-0"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3786"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12880"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3838"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.11.038"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13685"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-017-2648-0"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.4161\/jkst.25301"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4624"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.2.175"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1502863"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323896111"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14151"},{"key":"e_1_2_12_17_1","unstructured":"Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention 2020. Available from:www.ginasthma.org"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00124-7"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S275068"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.02.002"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31191-1"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.042"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0702-4"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314768"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12830"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.03.1079"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2011.01225.x"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.10.013"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(20)32766-9"},{"key":"e_1_2_12_34_1","first-page":"A6444","article-title":"Dupilumab rapidly and significantly improves lung function and decreases inflammation by 2 weeks after treatment initiation in patients with uncontrolled persistent asthma","volume":"195","author":"Papi A","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.19330"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200635972"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.1.51.pe55"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA117.001364"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.4509"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.113759"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxy048"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13421"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.7.4352"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.148.4.1086"},{"issue":"4","key":"e_1_2_12_46_1","first-page":"469","article-title":"Nitric oxide and superoxide in inflammation and immune regulation","volume":"54","author":"Guzik TJ","year":"2003","journal-title":"J Physiol Pharmacol"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.2.218"},{"key":"e_1_2_12_48_1","first-page":"A5949","article-title":"Type 2 biomarkers associated with dupilumab efficacy in patients with uncontrolled moderate\u2010to\u2010severe asthma enrolled in the phase 3 study LIBERTY ASTHMA QUEST","volume":"197","author":"Wenzel S","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.02.002"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2017.02.006"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.05.010"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0963"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.07.016"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.296"},{"issue":"106","key":"e_1_2_12_55_1","first-page":"TP1086","article-title":"Dupilumab in adolescents with moderate\u2010to\u2010severe atopic dermatitis by asthma comorbidity: subgroup analysis from a 16\u2010week randomized phase 3 trial","volume":"74","author":"Boguniewicz M","year":"2019","journal-title":"Allergy"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.297"},{"issue":"64","key":"e_1_2_12_57_1","first-page":"1115","article-title":"An improved assay for detection of sputum periostin in patients with asthma","volume":"56","author":"James A","year":"2020","journal-title":"Eur Resp J"},{"key":"e_1_2_12_58_1","unstructured":"DellonES RothenbergME CollinsMH et al.Dupilumab efficacy and safety in adult and adolescent patients with eosinophic esophagitis: results from part A of a randomized placebo controlled three\u2010part phase 3 study. Presented at UEG Week; E\u2010congress 2020;AB LB22."},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-015-0592-3"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13954","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cea.13954","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cea.13954","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T01:31:19Z","timestamp":1693359079000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cea.13954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,26]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["10.1111\/cea.13954"],"URL":"https:\/\/doi.org\/10.1111\/cea.13954","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,26]]},"assertion":[{"value":"2020-12-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}